UnitedHealth
UNH Mega CapHealthcare · Healthcare Plans
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
UnitedHealth en bref
UnitedHealth (UNH) is currently trading at 349,35 € with a market capitalization of 317,3 Md €. The trailing P/E ratio stands at 30.15x, with a forward P/E of 19.17x. The 52-week range spans from 204,52 € to 362,64 €; the current price is 3.7% below the yearly high. Year-over-year revenue growth stands at +2.0%. The net profit margin stands at 2.68%.
💰 Dividende
UnitedHealth currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
26 analystes évaluent UnitedHealth (UNH) au consensus : Acheter. L'objectif de cours moyen est de 355,14 €, soit un potentiel de +1.66% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 250,20 € à 428,91 €.
UnitedHealth : la thèse d'investissement en détail
UnitedHealth (UNH) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario baissier
Revenue growth has slowed to just 2%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 2.68%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.
Valorisation en contexte
The PEG ratio at 1.41 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
À surveiller
- The forward P/E of 19.17x is meaningfully below the trailing 30.15x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 91.6% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Free cash flow positif
- –Faible rentabilité (marge 2.68%)
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy UnitedHealth?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
